Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results

Prescription for Depression – Whether Cancer Patient or Caregiver
May 26, 2016
London liver transplant research breaks new ground 
May 26, 2016
Show all

Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results

A new medication is showing positive results in terms of clinical response and remission for those with moderate to severe Crohn’s disease.

Janssen Pharmaceuticals’ drug candidate Stelara (ustekinumab) demonstrated positive therapeutic effects in a recent Phase 3 clinical trial, inducing clinical response and remission in adult patients with moderate to severe Crohn’s disease who had been treated with anti-tumor necrosis factor (TNF)-alpha therapy and were either unresponsive or intolerant to it.

The efficacy and safety results from the Second Stelara Phase 3 Induction Study (UNITI-1) were presented at the 11th Congress of the European Crohn’s and Colitis Organization. Janssen has submitted applications, currently under review, with the U.S. FDA and the European Medicines Agency seeking approval of Stelara for the treatment of moderate to severe Crohn’s disease.

Stelara is a monoclonal antibody antagonist of human interleukin-12 and interleukin-23, molecules that are believed to play a role in the autoimmunity that leads to diseases such as Crohn’s.

Janssen launched a comprehensive Phase 3 UNITI clinical development program which included three studies, UNITI-1, UNITI-2 and IM-UNITI. Data from the UNITI-2 study, which evaluated Stelara for the treatment of patients who had failed conventional therapy but were mostly naïve to treatment with anti-TNF-alpha, was presented at the 2015 American College of Gastroenterology Annual Meeting and United European Gastroenterology Week. Data from the IM-UNITI maintenance study will be presented at a future medical congress.

The placebo-controlled UNITI-1 study enrolled 741 adult patients with moderate to severe Crohn’s disease who were randomized to receive either a single IV infusion of placebo, Stelara 130 mg, or Stelara ~6 mg/kg. The study’s primary endpoint was the clinical response at week six, measured through the reduction by at least 100 points in the Crohn’s Disease Activity Index (CDAI) score. Secondary endpoints included, at week eight, clinical response and clinical remission.

Read Full Article: Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results | IBD News Today

Read Full Article: Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results | IBD News Today

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.